Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenjun Cheng

Showing results (161-170 of 163) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 163 results.
Frontiers in Medicine|May 16, 2022
Prognostic-Related Metabolic Score for Survival Prediction in Early-Stage Endometrioid Endometrial Cancer: A Multi-Center and Retrospective StudyZizhuo Wang, Kun Song, Jingbo Liu, et al.
Frontiers in Medicine|May 2, 2022
Risk Factors and Prognosis of Early Recurrence in Stage I-II Endometrial Cancer: A Large-Scale, Multi-Center, and Retrospective StudyYingyu Dou, Kun Song, Yu Fu, et al.
CA: a Cancer Journal for Clinicians|November 25, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trialLingying Wu, Jing Wang, Qingshui Li, et al.
Pageof 17

Showing results (161-170 of 163) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 163 results.
Frontiers in Medicine|May 16, 2022
Prognostic-Related Metabolic Score for Survival Prediction in Early-Stage Endometrioid Endometrial Cancer: A Multi-Center and Retrospective StudyZizhuo Wang, Kun Song, Jingbo Liu, et al.
Frontiers in Medicine|May 2, 2022
Risk Factors and Prognosis of Early Recurrence in Stage I-II Endometrial Cancer: A Large-Scale, Multi-Center, and Retrospective StudyYingyu Dou, Kun Song, Yu Fu, et al.
CA: a Cancer Journal for Clinicians|November 25, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trialLingying Wu, Jing Wang, Qingshui Li, et al.
Pageof 17